[1] Liuzzi G, Chirianni A, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS. 1996;10:F51-6.
[2] Stekler JD, Ure G, Dragavon J, Chang M, Coombs RW. Detection of HIV RNA in dried blood spots and oral fluids. AIDS. 2017;31:1191-3.
[3] Benzekri NA, Sambou JF, Ndong S, Tamba IT, Faye D, Diallo MB, et al. Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, West Africa. BMC Infect Dis. 2019;19:261.
[4] Stekler J, Sycks BJ, Holte S, Maenza J, Stevens CE, Dragavon J, et al. HIV dynamics in seminal plasma during primary HIV infection. AIDS Res Hum Retroviruses. 2008;24:1269-74.
[5] Mujugira A, Coombs RW, Heffron R, Celum C, Ronald A, Mugo N, et al. Seminal HIV-1 RNA detection in heterosexual African men initiating antiretroviral therapy. J Infect Dis. 2016;214:212-5.
[6] Pavlinac PB, Hawes SE, Gottlieb GS, Gaye A, N'Diaye CF, Critchlow CW, et al. HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors. Sex Transm Infect. 2012;88:45-50.
[7] Balamane M, Winters MA, Dalai SC, Freeman AH, Traves MW, Israelski DM, et al. Detection of HIV-1 in saliva: implications for case-identification, clinical monitoring and surveillance for drug resistance. Open Virol J. 2010;4:88-93.
[8] Di Zazzo A, Micera A, De Piano M, Cortes M, Bonini S. Tears and ocular surface disorders: Usefulness of biomarkers. J Cell Physiol. 2019;234:9982-93.
[9] Nizamuddin I, Koulen P, McArthur CP. Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands. Int J Mol Sci. 2018;19:2747.
[10] Agrawal R, Balne PK, Verapan A, Au VB, Lee B, Loo E, et al. A distinct cytokines profile in tear film of dry eye disease (DED) patients with HIV infection. Cytokine. 2016;88:77-84.
[11] Balne PK, Agrawal R, Au VB, Lee B, Loo E, Tong L, et al. Dataset of longitudinal analysis of tear cytokine levels, CD4, CD8 counts and HIV viral load in dry eye patients with HIV infection. Data Brief. 2017;11:152-4.
[12] Mueller AJ, Klauss V, Gürtler L, Geier S. Infrequent detection of HIV-1 components in tears compared to blood of HIV-1-infected persons. Infection. 1992;20:249-52.
[13] Han Y, Wu N, Zhu W, Li Y, Zuo L, Ye J, et al. Detection of HIV-1 viruses in tears of patients even under long-term HAART [Letter]. AIDS. 2011;25:1925-7.
[14] Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, et al; Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy. J Infect Dis. 2017;215:105-13.
[15] Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001;15:837-45.
[16] Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, et al. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol. 2000;38:1414-8.
[17] Fiore JR, Suligoi B, Saracino A, Di Stefano M, Bugarini R, Lepera A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17:2169-76.
[18] Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, et al. HIV-1 RNA Levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS Clinical Trials Group Study A5077. PLoS One. 2014;9:e93537.
[19] Fujikawa LS, Salahuddin SZ, Palestine AG, Masur H, Nussen-blatt RB, Gallo RC. Isolation of human T-lymphotropic virus type III from the tears of a patient with the acquired immunodeficiency syndrome. Lancet. 1985;2:529-30.
[20] Kunavisarut P, Sirirungsi W, Pathanapitoon K, Rothova A. Clinical manifestations of human immunodeficiency virus-induced uveitis. Ophthalmology. 2012;119:1455-9.
[21] Williams-Wietzikoski CA, So ID, Bull ME, Samleerat T, Pathanapitoon K, Kunavisarut P, et al. Genetic analyses of HIV env associated with uveitis in antiretroviral-naïve individuals. AIDS. 2017;31:1825-30.
[22] Pathanapitoon K, Riemens A, Kongyai N, Sirirungsi W, Leechanachai P, Ausayakhun S, et al. Intraocular and plasma HIV-1 RNA loads and HIV uveitis. AIDS. 2011;25:81-6.
[23] Christo PP, Greco DB, Aleixo AW, Livramento JA. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis. 2007;7:147.
[24] Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immuno. 2006;13:1111-8.
[25] Ikeno R, Yamada E, Yamazaki S, Ueda T, Nagata M, Takagi R, et al. Factors contributing to salivary human immunodeficiency virus type-1 levels measured by a Poisson distribution-based PCR method. J Int Med Res. 2018;46:996-1007.
[26] Kunavisarut P, Sirirungsi W, Pathanapitoon K, Rothova A. Clinical manifestations of human immunodeficiency virus-induced uveitis. Ophthalmology. 2012;119:1455-9.
[27] Rothova A, Schneider M, de Groot-Mijnes JD. Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads. Ophthalmology. 2008;115:2062-4.
[28] Gomes P, Carvalho AP, Diogo I, Gonçalves F, Costa I, Cabanas J, et al. Comparison of the NucliSENS EasyQ HIV-1 v2.0 with Abbott m2000rt RealTime HIV-1 assay for plasma RNA quantitation in different HIV-1 subtypes. J Virol Methods. 2013;193:18-22.
[29] Katsoulidou A, Rokka C, Issaris C, Haida C, Tzannis K, Sypsa V, et al. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. Virol J. 2011;8:10.
[30] Amendola A, Marsella P, Bloisi M, Forbici F, Angeletti C, Capobianchi MR. Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays. J Clin Microbiol. 2014;52:2019-26.
[31] Garner W, White K, Szwarcberg J, McCallister S, Zhong L, Wulfsohn M. Concordance of HIV-1 RNA values by Amplicor and TaqMan 2.0 in patients with confirmed suppression in clinical trials. Clin Infect Dis. 2016;62:929-34.
[32] Lalama CM, Jennings C, Johnson VA. Comparison of three different FDA-approved plasma HIV-1 RNA assay platforms confirms the virologic failure endpoint of 200 copies per milliliter despite improved assay sensitivity. J Clin Microbiol. 2015;53:2659-66.
[33] Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis. 1999;179:S431-5